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INTRODUCTION
Since the first orthotopic implantation of an allograft
aortic valve more than 30 years ago (1-4), allograft
aortic and pulmonary valves have been increasing-
ly used in the surgical management of aortic valve
and aortic root disease (5-8), as well as for the cor-
rection of complex congenital heart disease (9-15),
and their usefulness is not deniable. Although early
allograft valves were variably sterilized in ethylene
oxide, preserved in β -propriolactone, irradiated, or
freeze-dried, subsequent developments in preserva-
tion techniques including antibiotic use (16), improved
culture media, and freezing have led to the use of
cryopreserved allograft valves. The most common
cryopreservation method involves freezing in dimethyl
sulfoxide and storage with liquid nitrogen (16).
Although aortic valve replacement with cryopreserved
allograft valves achieves excellent early results, even-
tual failure of these tissues is common (17-20). Despite
long-standing and widespread use of cryopreserved
allograft valves, the basic cellular biology of these
tissues is unknown. Ongoing particular interests and
controversies concern allograft valve cellular viabil-
ity (21-27), the contribution of the immune response
mainly caused by viable donor cells (28, 29), and the
preservation and regeneration of intrinsic extracellular
matrix. It is unclear how may these factors may be
associated with valve durability and competence. The
present study was undertaken to review the biology
of cryopreserved valves relevant to long-term durabil-
ity and “better” preservation techniques.
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ability was activated immediately after the thawing process. These findings imply that the
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The most common cryopreservation method
Cryopreservation techniques include four processes
as follows : first, sterilization ; second, freezing ; third,
storage ; and fourth, thawing.
1) Sterilization : Presently, the most commonly
used and widely accepted method for allograft
tissues is broad-spectrum antibiotics in a nu-
trient medium (Fig. 1).
2) Freezing : Freezing rate of -1℃ per minute would
be best to maximize fibroblast viability (30-32)
(Fig. 2). Freezing is done kinetically in the pres-
ence of a cryoprotectant such as glycerol or
dimethyl sulfoxide. As the allograft temper-
ature approaches -20℃, most of extracellular
water has frozen, and the remaining freezing
medium has begun to solidify. The release of
heat associated with water crystallization rap-
idly diminishes at this point. To maintain a
consistent -1℃ per minute freezing rate, the
chamber must be rewarmed to temperatures
just below that of the allografts. From this point,
the temperature, which declines within the
chamber, is directly reflected in parallel with
the temperature decline of the allograft tissue.
3) Storage : A convenient storage system is the va-
por phase of a liquid nitrogen freezer (-196℃).
4) Thawing : Fast warming is usually desirable and
has been recommended with heart valves. The
actual achievable warming rate is dependent
upon the total volume of the graft and solution,
the insulating qualities of the packaging, and
temperature of the thawing medium. Thawing
time is commonly 12-14 min (～15℃/min) for
aortic and pulmonary valued conduits with a
total combined volume of 100 ml for valve and
medium.
Fig. 1. Procurement, sterilization, and packaging of pulmonary valve.
A : The pulmonary valve is dissected and procured within one hour after
death.
B : After antibiotic sterilizing treatment (240 µg/ml cefazolin, 120 µg/ml
lincomycin, 50 µg/ml vancomycin, and100 µg/ml polymixin B) at 4℃
for 24 hours, valves were transferred to TC199 culture medium with
5% N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer, 10% calf
serum, and 10% dimethyl sulfoxide.
Fig. 2. Computer-controlled freezing curve.
In our institute, the heart valve is frozen with a programmable
freezer (Cryomed model 1050, Forma Scientific Co, Marietta,
Ohio). Solid line shows the temperature within the chamber.
Dotted line shows the temperature of the tissue.
(1) Temperature within the chamber is kept at 4℃.
(2) Released heat associated with water crystallization around
-20℃- -30℃ is regulated.
(3) Freeze the sample to -80℃ (-1℃/min).
?
?
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Cellular viability of cryopreserved valves
The rarity of valve tissue degeneration of pulmo-
nary autografts and the demonstration that these
autografts can grow does suggest that autogenous
valve tissue with intact endothelial and fibroblast cells
has distinct advantages over allograft valve tissue
(33). Several studies suggested that allograft valve
viability associated with cryopreservation techniques
was recognized as one of the most influencing factors
on the long-term durability of cryopreserved allograft
valves (34, 35).
Questions of cryopreservation techniques are par-
ticularly relevant in addressing allograft valve viabil-
ity and the ability to repair leaflet wear and tear injury.
It is unclear whether viable donor cells, including
intrinsic cuspal interstitial tissue cells, mainly con-
sisting of fibroblasts, and endothelial cells, are present
at the time of implantation of cryopreserved allograft
valves and whether they persist over the long term.
In addition, it is unknown if long-term hemodynamic
competence of implanted cryopreserved allograft
valves requires donor cell viability and the regenera-
tion of the intrinsic extracellular matrix.
Hillbert et al . reported that apoptosis occurred in
endothelial cells and cuspal interstitial tissue cells of
implanted cryopreserved allograft valves, and this might
lead to their loss of cellularity (36). This apoptosis
may be related to various factors, including immu-
nologic and chemical injury, and hypoxia during
valve processing and reperfusion injury at the time of
implantation. Whether the apoptosis and acellularity
or patchy cellularity commonly observed in clinically
explanted allograft valves is due to cryopreservation
techniques themselves remains to be determined
(37).
1) Fibroblasts viability
If the cell viability in allograft aortic valves is cru-
cial in determining the long-term fate of the valves,
then the specific cell population of the greatest im-
portance is likely to be the fibroblasts. These cells
are by far the most abundant in aortic valves and
are responsible for protein synthesis and structur-
al integrity. Prolonged valve competence and du-
rability of cryopreserved valves have been suggested to
be derived from the viability of the donor fibroblasts,
which can remodel the matrix assembly (28, 29).
VanderKamp et al. (30-32) demonstrated that a
constant -1℃ per minute freezing would be the best
rate to maximize the fibroblast viability, and this theo-
ry was adopted and has been used as a freezing stan-
dard by the clinical tissue bank (e.g. : Cryolife, Inc.,
Marietta, Ga.). For heart valves, the presence of a
high percentage of the fibroblasts which are capable
of resynthesizing the collagenous matrix of the valve,
as well as maintaining mechanical integrity, is the
primary consideration (31, 38, 39).
The viability of any tissue after cryopreservation
was suggested to be dependent, in part, upon handling
during procurement and prefreezing storage (22-25).
Any exposure to non-physiological conditions, such
as ischemia, hypoxia, or anoxia causes direct toxicity
to most cell types, with subsequent stresses of freez-
ing and thawing (27). Although previous examina-
tions of allograft aortic valves have successfully dem-
onstrated the presence or absence of endothelial cell
viability in vivo , viability of the fibroblast population
has not been demonstrated except in an in vitro model
(37). Unlike the endothelial cells, whose relatively
rapid rate of replication allows convenient methods
of assessing their viability, the fibroblast cells rep-
licate slowly and less predictably. Consequently, the
evaluation of in vivo fibroblast viability requires a
method of study that is based on normal metabolic
activities of the cell.
There are some experimental studies that favor
persistence of donor fibroblast viability after implan-
tation (21-25). Niwaya et al . reported that fibroblast
viability of the cryopreserved human allograft valve
was well preserved (>70%) with a warm ischemic time
of less than 520 minutes by flow cytometry (24).
Fibroblasts exist within the noncellular matrix, which is
composed primarily of collagen, elastin, and proteoglycans
(40). Collagen represents the largest portion of the
extracellular matrix in the aortic valve. Maintenance
of the normal collagen synthesis may be important
for the preservation of normal tissue structure and
function. If the cellular viability of the fibroblasts helps
to determine the capacity of the graft to resist de-
terioration, this may be mediated by collagen pro-
duction. Lupinetti et al. demonstrated that allografts
retain a persistent capacity for procollagen synthe-
sis of fibroblasts similar to that of the native aortic
valve (41, 42). However, some clinical studies did
not favor donor fibroblast viability after implantation
(37). Although persistence of donor fibroblasts has
been demonstrated, the histological finding of explanted
cryopreserved allograft valves, including allograft
valves explanted for reasons other than degenera-
tion, showed acellularity or rare cellularity or patchy
cellularity of leaflets (37). The demonstration that
fibroblasts of homogenized recently cryopreserved
aortic valve tissue can incorporate tritiated glycine
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into collagen after short-term implantation (21, 43)
does not necessarily translate into the long-term
postimplantation ability to repair and regenerate
leaflet structure, which is implied by the term “viable”.
Our previous study demonstrated that the cytosolic
function of cusps, mainly consisting of fibroblasts, was
comparatively preserved ; however, the mitochondrial
function was still more diminished during these pro-
cesses (44). These findings imply that cryopreservation
causes a latent injury even in fibroblasts, which may
cause valve failure after implantation. Lu et al . also
reported that the mitochondrial dehydrogenase ac-
tivity of the porcine valve was significantly dimin-
ished after cryopreservation processing (45).
2) Endothelial cell viability and immunogenicity
The importance of endothelial cells to the long-term
fate of allograft valves is unknown. Functions of the
vascular endothelium include resistance to throm-
bosis, maintenance of hemostasis, and modulation
of vascular smooth muscle activity. Mediation of im-
munologic and inflammatory responses is another
function of endothelium that is particularly impor-
tant for allograft valves (46). The vascular endo-
thelium constitutively expresses Class I antigen and
is induced to express Class II antigens when it is
exposed to an allogenic milieu (47-49). According-
ly, vascular endothelium is considered to be themost
immunostimulatory component of the whole organ
allografts. Whether this property of vascular endo-
thelium is applicable to the endothelium of dynamic
valves and can be markedly altered by cryopreservation
remains to be determined.
First, several studies have reported on the viability
and function of donor endothelial cells of cryopreserved
allograft valves (6, 50-53). Yankah et al . described
70% to 80% endothelial cell viability in cryopreserved
human allograft valves (54, 55). However, Lupinetti
et al. demonstrated that viable endothelial cells were
only observed on 21 of 131 (16%) cryopreserved allograft
specimens (51).
Most previously published studies examining the
cellular viability of allograft valves used specimens
obtained immediately after harvest, disinfection, or
thawing, but not after subsequent implantation. Thus,
influences of implantation, including immunologic
consequences, were not considered. Such studies
may not be able to predict long-term cellular viabil-
ity in implanted valves (44, 50, 51). Previous studies
demonstrated that early endothelial viability was well
maintained in fresh grafts, but completely abolished
in cryopreserved grafts. A previous study showed
a sharp divergence between the pathologic fate of
endothelium and that of fibroblast cells of cryopreserved
valves and emphasized the importance of analyzing
the cell populations independently. Our previous
study (44) revealed the cytosolic esterase activity of
cryopreserved human umbilical vein endothelial cells
fell to 28%±9.0% of fresh specimens, and mitochondrial
dehydrogenase activity fell to 44%±6.1%. These
findings suggest that cryopreservation appeared to
produce serious damage to cytosolic andmitochondrial
functions of endothelial cells. We presumed that the
cell membrane is easily damaged soon after harvest.
Mitochondria are the center of the intracellular en-
ergy source. The more the mitochondrial function
is aggravated due to cryopreservation process, the
more the cell membrane deteriorates due to energy
depletion.
Loss of the endothelium may contribute to enhanced
graft longevity by reducing the host immune response,
which may contribute to valve degeneration. However,
loss of the endothelium may increase the capacity
for thrombus formation and adversely affect the
underlying fibroblasts, thereby accelerating graft
deterioration. It is unknown to what extent valve de-
generation is attributed to immune responses.
To elucidate the morphology, mechanisms of de-
terioration, cellular viability, extracellular matrix in-
tegrity, and the role of immune responses in the
dysfunction of cryopreserved allograft valves, Mitchell
et al. evaluated explanted cryopreserved allograft valves
and compared them with aortic valves removed from
short-term and long-term transplanted hearts (18).
Cryopreserved allograft valves are morphologically
nonviable ; their collagen is flattened but largely
preserved (18). They are unlikely to grow, remodel,
or exhibit active metabolic functions, and their usual
degeneration cannot be attributed to immunologic
responses. In contrast aortic valves of transplanted
hearts maintain near-normal overall architecture and
cellularity and do not show apparent immunologic in-
jury, even in the setting of fatal myocardial parenchymal
rejection or graft arteriosclerosis. Allografts implanted
for more than one day showed progressive collagen
hyalinization and loss of normal structural complex-
ity and cellularity including endothelium and deep
connective tissue cells. Inflammatory cells were gen-
erally minimal or absent in the allografts. Cryopreserved
allograft valves have minimal viable cells, but large-
ly retain the original collagen network ; preservation
of autolysis-resistant collagenous skeleton probably
provides the structural basis of function. Although,
in some studies, short-course immunosuppression
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has been recommended to prevent early failure of
allograft valves (56), in another study, the usual de-
generation was not derived from immunological re-
sponses. These findings suggest that the immunogenicity
of cryopreserved allograft valves can be markedly
altered and disappears by cryopreservation process.
However, Mohan et al. insisted that after “better”
cryopreservation, the endothelial cell function is
similar to that of normal endothelium and that “a
lack of viable endothelium” suggests that “preser-
vation of the remaining valve may be the suspect”
(22). Cryopreservation must aim to preserve a viable
endothelial lining, because its loss could be the main
reason behind the accelerated thrombosis, calcifica-
tion, and infection of commercial bioprosthetic valves.
Unfortunately, there is currently no clinical informa-
tion to support this position. Using the occurrence
of “accelerated thrombosis, calcification, and infec-
tion of commercial bioprosthetic valves”, that is with-
out endothelial lining as justification for preserving
the endothelium of allografts is not sufficient.
It cannot yet be determined whether rare endo-
thelial cells or a viable endothelial lining has a posi-
tive, negative, or neutral effect on the long-term struc-
ture and function of cryopreserved allograft aortic
and pulmonary valves, respectively.
Collagen synthesis and collagenolysis
For the long-term performance of cryopreserved
allograft valves, a more important factor may be pre-
serving the intactness of the original collagen net-
work (36) that provides the structural basis of the
valve matrix (Fig. 3). Despite the widespread use of
cryopreserved valves, the balance of collagen syn-
thesis and collagenolysis ability of the valves has not yet
been clearly revealed (57-59). Controlled collagenolysis
ability was suggested to play an important role in
the first step of the regeneration process (18), and
consequent collagen synthesis is a second step.
Lupinetti et al. (41, 42) demonstrated the pres-
ence of procollagen and the α1-(I) procollagen gene
expression in allograft aortic valves after implanta-
tion for 3 days, which suggested donor fibroblast
viability. Fibroblasts have been known to exist within
the matrix (40) and to participate in the valve remodeling
through collagen metabolism. In our previous study,
the collagen content in the cryopreserved cusps was
kept at the same degree as that of the fresh cusps,
and the collagen synthesis ability in the cryopreserved
cusps was also relatively preserved (43). However,
the protein synthesis ability, including collagen syn-
thesis, in the cryopreserved cusps decreased signifi-
cantly (43). Although the collagen synthesis ability
was preserved, like the findings of Lupinetti et al. (41,
42), such a marked reduction in protein synthesis abil-
ity may have had a significant impact on the long-term
cellular viability.
The matrix metalloproteinases (MMPs) are a fami-
ly of zinc-dependent enzymes that are able to digest
a wide range of extracellular matrix proteins (60-
62). The expression of the MMPs from the endo-
thelial cells (63, 64), the fibroblast cells (65, 66),
and ischemic myocardium (67, 68) was consecutive-
ly revealed (63, 64). MMP-1, an interstitial collagenase,
is mainly produced from fibroblasts, and is known
to degrade structural type I collagen in the matrix.
MMP-2 and MMP-9 are mainly produced from the
endothelium, and are known to be involved in the
degradation of type IV collagen, which is a major
component of the subendothelial basement mem-
brane (Fig. 4).
Our previous study demonstrated that the cytosolic
Fig. 3. Photomicrograph of a section from a cryopreserved heart valve.
Cusp of the porcine heart valve is stained with Sirius red (Muto Pure Chemi-
cals, Tokyo, Japan), which is a dye selective to collagen. Collagen fibers
stained red. (Original magnification×200).
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and mitochondrial function of endothelial cells were
seriously damaged during the cryopreservation and
thawing processes (44), and those processes may
cause a latent cytosolic and mitochondrial injury
even in the fibroblasts. Despite the anticipated re-
duced cellular viability, particularly endothelial cells,
in the cryopreserved cusps, the activity of the MMP-1
and MMP-2 in the supernatant of the cryopreserved
cusps was observed at the quantitatively same degree
as those of the fresh cusps (43). These findings im-
ply that the cryopreservation and thawing process
causes MMP-1 and MMP-2 release from endothelial
and fibroblast cells of allograft cusps, and activates
them before the implantation (Fig. 5). There is a
possibility that the activated MMP-2 will degrade the
basement membrane consisting of type IV collagen
and activated MMP-1 will destruct the cusp matrix.
Most cryopreserved valves may have the potential
to degrade and autolyze the matrix extensively during
processing, intraoperative preparation, and possibly
after implantation.
From these apparently discrepant results, it is suggested
that the collagen synthesis ability is preserved even
in the slightly injured fibroblast cells of cryopreserved
valves, however, the protein synthesis ability might
be extremely reduced because of limited endothelial
Fig. 4. Action of the MMPs in heart valve.
Cellular components of heart valve consist of fibroblasts and endothelial cells. Between both, there is a basement membrane, which
is known to consist of type IV collagen. Most of the matrix of the heart valve consists of type I collagen fibers. The endothelial cells
and the fibroblasts have a potential to secret collagenase, MMPs. This schema shows the site of the action of MMP-1 and MMP-2.
MMP-1 mainly participates in the degradation of type I collagen and MMP-2 degrades type IV collagen.
Fig. 5. Hypothetical role of MMPs in the cryopreserved heart valve.
In the cryopreserved heart valve, the cryopreservation processes significantly degrade the endothelial cells covered on the base-
ment membrane. It seems that exposed basement membrane is easily targeted by the MMPs secreted from the damaged endo-
thelial cells.
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collaboration (43, 69, 70) and the decrease in the
protein production relevant to the intracellular organellar
function (44), which maintains the cell viability, and
that the collagenolytic activation occurs just before
implantation (43). With respect to those findings, the
injured fibroblasts are going to be non-viable, col-
lagen synthesis is suggested to deteriorate, and the
original collagenous skeleton degrades in the near
future. The collagenolysis dominant state was sus-
pected in the cryopreserved valves.
Although it is necessary to elucidate the dynam-
ics of tissue inhibitors of MMPs in the cryopreserved
valves, the control of the MMPs activity in the
cryopreserved valves may become more effective
to obtain the long-term durability rather than the
preservation of collagen synthesis ability. Recently,
there were some reports that doxycycline, a deriva-
tive of tetracycline, suppresses the development of
the elastase induced abdominal aortic aneurysms
(71, 72), through the direct MMPs-inhibiting activi-
ties. Other MMPs inhibitors, marimastat (BB-2516),
batimastat (BB-94) and BE16627B, were also de-
veloped as agents for inhibiting cancer metastasis
(73-75). These agents might improve the allograft
preservation in clinical use.
In conclusion, the findings of this review suggest
the possibility that the current cryopreservation tech-
niques and management, themselves, may lead a
cryopreserved valve to become non-viable acellular
tissue by the collagenolytic activation and degrada-
tion of protein synthesis, which will cause the de-
struction of the valve matrix. Further examination of
collagen metabolism and modulation of the collagenolytic
activity will be necessary to improve the allograft
preservation for better clinical use. We believe that
the enthusiasm for allograft tissue implantation should
be considered in the overall context of allograft fail-
ure.
REFERENCES
1. Ross DN : Homograft replacement of the aortic
valve. Lancet 2 : 487, 1962
2. Ross DN : Replacement of the aortic and mitral
valves with a pulmonary autograft. Lancet 2 :
956 -958, 1967
3. Eguchi S, Asano K : Homograft of pulmonary
artery or ascending aorta with valve as a right
ventricular outflow. J Thorac Cardiovasc Surg
56 : 413-420, 1968
4. Barratt-Boyes BG, Roche AH, Whitoloch RM :
Six year review of the results of freehand aor-
tic valve replacement using an antibiotic steri-
lized homograft valve. Circulation 55 : 353-361,
1977
5. Okita Y, Franciosi G, Matsuki O, Robles A, Ross
DN : Early and late results of aortic root replace-
ment with antibiotic-sterilized aortic homograft.
J Thorac Cardiovasc Surg 95 : 696-704, 1988
6. Haydock D, Barratt-Boyes B, Macedo T, Kirklin
JW, Blackstone E : Aortic valve replacement for
active infectious endocarditis in 108 patients :
a comparison of freehand allograft valves with me-
chanical prostheses and bioprostheses. J Thorac
Cardiovasc Surg 103 : 130-139, 1992
7. Chambers JC, Somerville J, Stone S, Ross DN :
Pulmonary autograft procedure for aortic valve
disease : long-term results of the pioneer series.
Circulation 96 : 2206-2214, 1997
8. Niwaya K, Knott-Craig CJ, Santangelo K, Lane
MM, Chandrasekaran K, Elkins RC : Advantage
of autograft and homograft valve replacement
for complex aortic valve endocarditis. Ann Thorac
Surg 67 : 1603-1608, 1999
9. Gerosa G, McKay R, Davies J, Ross DN : Com-
parison of the aortic homograft and the pulmo-
nary autograft for aortic valve or root replace-
ment in children. J Thorac Cardiovasc Surg
102 : 51-61, 1991
10. Michler RE, Chen JM, Quaegebeur JM : Novel
technique for extending the use of allografts in
cardiac operations. Ann Thorac Surg 57 : 83-87,
1994
11. Stark J : The use of valved conduits in pediat-
ric cardiac surgery. Pediatr Cardiol 19 : 282-288,
1998
12. Perron J, Moran AM, Gauvreau K, del Nido PJ,
Mayer Jr JE, Jonas RA : Valved homograft con-
duit repair of the right heart in early infancy.
Ann Thorac Surg 68 : 542-548, 1999
13. Dittrich S, Alexi-Meskishvili VV, Yankah AC,
Dahnert I, Meyer R, Hetzer R, Lange PE : Com-
parison of porcine xenografts and homografts
for pulmonary valve replacement in children. Ann
Thorac Surg 70 : 717-722, 2000
14. Yoshikawa Y, Kitamura S, Taniguchi S, Kameda
Y, Niwaya K, Sakaguchi H : Pulmonary ventricu-
lar outflow reconstruction with a size-reduced
cryopreserved pulmonary valve allograft : mid-term
follow up. Jpn Circ J 64 : 23-26, 2000
15. Matsuki O, Okita Y, Almeida RS, McGoldrick
JP, Hooper TL, Robles A, Ross DN : Two dec-
１２９The Journal of Medical Investigation Vol. 48 2001
ades’ experience with aortic valve replacement
with pulmonary autograft. J Thorac Cardiovasc
Surg 95 : 705-711, 1988
16. Lange PL, Hopkins RA : Cardiac reconstruction
with allograft valves. Springer-Verlag, NewYork,
1989, pp 46-53
17. Salim KA, DiSessa TG, Alpert BS, Arheart KL,
Novick WM, Watson DC : The fate of homograft
conduits in children with congenital heart
disease : an angiographic study. AnnThorac Surg
59 : 67-73, 1995
18. Mitchell RN, Jonas RA, Schoen FJ. Pathology
of explanted cryopreserved allograft heart valves :
comparison with aortic valves from orthotopic
heart transplants. J Thorac Cardiovasc Surg 115 :
118-127, 1998
19. LeBlanc JG, Russell JL, Sett SS, Potts JE : Inter-
mediate follow-up right ventricular outflow tract
reconstruction with allograft conduits. Ann Thorac
Surg 66 : S174 -178, 1998
20. Stark J, Bull C, Stajevic M, Jothi M, Elliott M,
de Leval M : Fate of subpulmonary homograft
conduits : determinants of late homograft fail-
ure. J Thorac Cardiovasc Surg 115 : 506-516,
1998
21. Al-Janabi N, Gonzalez-Lavin L, Neirotti R, Ross
DN : Viability of fresh aortic valve homografts :
a quantitative assessment. Thorax 27 : 83-86, 1972
22. Brockbank KGM : Cell viability in fresh, refrig-
erated, and cryopreserved human heart valve
leaflets. Ann Thorac Surg 49 : 848-849, 1990
23. Lang SJ, Giordano MS, Carlon-Cardo C, Summers
BD, Statiano-Coico L, Hajjar DP : Biochemcal
and cellular characterization of cardiac valve tis-
sue after cryopreservation or antibiotic preser-
vation. J Thorac Cardiovasc Surg 108 : 63-67,
1994
24. Niwaya K, Sakaguchi H, Kawachi K and Kitamura
S : Effect of warm ischemia and cryopreservation
on cell viability of human allograft valves. Ann
Thorac Surg 60 : S114 -117, 1995
25. Gall KL, Smith SE, Willmette CA, O’Brien MF :
Allograft heart valve viability and valve-processing
variables. Ann Thorac Surg 65 : 1032 -1038, 1998
26. O’Brien MF, Johnston N, Stafford G, Gardner
M, Pohlner P : A study of the cells in the explanted
viable cryopreserved allograft valve. J Card Surg
3 : 279 -287, 1988
27. Wassenaar C, Wijsmuller EG, Van Herwerden
LA, Aghai Z, Van Tricht CLJ, Bos E : Cracks in
cryopreserved aortic allografts and rapid thaw-
ing. Ann Thorac Surg 60 : S165 -167, 1995
28. Arminger LC : Postimplantation leaflet cellularity
of valve allografts : are donor cells beneficial or
detrimental? Ann Thorac Surg 66 : S233-235,
1998
29. Koolbergen DR, Hazekamp MG, Kurvers M,
de Heer E, Cornelisse CJ, Huysmans HA, Bruijn
JA : Tissue chimerism in human cryopreserved
homograft valve explants demonstrated dem-
onstrated by hybridization. Ann Thorac Surg
66 : S225-232, 1998
30. Van Der Kamp AWM, Nauta J : Fibroblast func-
tion and the maintenance of the aortic-valve
matrix. Cardiovasc Res 13 : 167-172, 1979
31. Van Der Kamp AWM, Visser WJ, Dongen JM,
Nauta J, Galjaard H : Preservation of aortic heart
valves with maintenance of cell viability. J Surg
Res 30 : 47-56, 1981
32. Mochtar B, Van Der Kamp AWM, Jongh EJ,
Nauta J : Cell survival in canine aortic heart valves
stored in nutrient medium. Cardiovasc Res 18 :
497-501, 1984
33. Heacox AE, McNally RT, Brockbank KGM :
Factors affecting the viability of cryopreserved
allograft heart valves. In : Yankah AC, Hetzer R,
Miller DC, Ross DN, Sommerville J, Yacoub
MH, eds. Cardiac valve allografts 1962-1987.
Springer-Verlag, New York, 1988, pp 37-41
34. O’Brien MF, Stafford EG, Gardner MA, Pohlner
PG, McGiffin DC : A Comparison of aortic valve
replacement with viable cryopreserved and fresh
allograft valves, with a note on chromosomal
studies. J Thorac Cardiovasc Surg 94 : 812-823,
1987
35. Angell WW, Oury JH, Lamberti JJ, Koziol J :
Durability of the viable aortic allograft. J Thorac
Cardiovasc Surg 98 : 48-55, 1989
36. Hilbert SL, Luna RE, Zhang J, Wang Y, Hopkins
RA, Yu Z, Ferrans VJ : Allograft heart valves :
the role of apoptosis-mediated cell loss. J Thorac
Cardiovasc Surg 117 : 454-462, 1999
37. Mitchell RN, Jonas RA, Schoen FJ : Structure-function
correlations in cryopreserved allograft cardiac
valves. Ann Thorac Surg 60 : S108-113, 1995
38. Brockbank KGM, Carpenter JF, Dawson P : Effects
of storage temperature on viable bioprosthetic
heart valves. Cryobiology 29 : 537-542, 1992
39. Hu JF, Hopkins R, Wolfinbarger I : Effects of
antibiotics on cellular viability in porcine heart
valve tissue. Cardiovasc Res 23 : 960-964, 1989
40. Broom ND : The observation of collagen and
elastin structures in wet whole mounts of pul-
monary and aortic leaflets. J Thorac Cardiovasc
T. Kitagawa et al. Cellular biology of cryopreserved allograft valves１３０
Surg 75 : 121-130, 1978
41. Lupinetti FM, Kneebone JM, Rekhter MD,
Brockbank KGM, Gordon D : Procollagen pro-
duction in fresh and cryopreserved aortic valve
grafts. J Thorac Cardiovasc Surg 113 : 102-107,
1997
42. Song YC, Yao LY, Kneebone JM, Lupinetti FM :
Effect of cryopreservation and histocompatibility
on type I procollagen gene expression in aortic
valve grafts. J Thorac Cardiovasc Surg 114 : 421-
427, 1997
43. Kano M, Masuda Y, Hori T, Yoshizumi M, Kitaichi
T, Wakisaka Y, Tominaga T, Yasuta O, Kitagawa
T : Collagen synthesis and collagenase activity
of cryopreserved heart valve. J Thorac Cardiovasc
Surg : 2001 in press
44. Tominaga T, KitagawaT,Masuda Y, Hori T, Kano
M, Yasuta O, Katoh I : Viability of cryopreserved
semilunar valves. an evaluation of cytosolic and
mitochondrial activities. Ann Thorac Surg 70 :
792-757, 2000
45. Lu JH, Chiu YT, Sung HW, Hwang B, Chong
CK, Chen SP, Mao SJ, Yang PZ, Chang Y :
XTT-colorimetric assay as a marker viability in
cryoprocessed cardiac valve. J Mol Cell Cardiol
29 : 1189-1194, 1997
46. Rocca FD, Sartore S, Guidolin D, Bertiplaglia B,
Gerosa G, Casarotto D, Pauletto P : Cell com-
position of the human pulmonary valve : a com-
parative study with the aortic valve-the VESALIO
project. Ann Thorac Surg 70 : 1594-1600, 2000
47. Cochran RP, Kunzelman KS : Cryopreservation
does not alter antigenic expression of aortic
allografts. J Surg Res 46 : 597-599, 1989
48. Lupinetti FM, Christy JP, King DM, Khatib HE,
Thompson SA : Immunogenicity, antigenicity,
and endothelial viability of aortic valves preserved
4℃ in a nutrient medium. J Cardiac Surg 6 :
454-461 1991
49. Quigley RL, Switzer DSS, Victor TA, Goldschmidt
RA, Salinger MH, Arentzen CE, Alexander JC,
Anderson RW : Modulation of alloreactivity in
transplant recipients by phenotypic manipula-
tion of donor endothelium. J Thorac Cardiovasc
Surg 109 : 905-909, 1995
50. Killinger Jr WA, Dorofi DB, Tinsley Jr EA, Keagy
BA, Johnson G : Flow cytometric analysis of or-
gan preservation-induced endothelial cell mem-
brane damage. Ann Thorac Surg 53 : 472-476,
1992
51. Lupinetti FM, Tsai TT, Kneebone JM, Bove
EL : Effect of cryopreservation on the presence
of endothelial cells on human valve allografts.
J Thorac Cardiovasc Surg 106 : 912-917, 1993
52. Mohan R, Feng XJ, Walter P, Herman A :
Cryopreserved heart valve allografts can have
a normal endothelium. J Thorac Cardiovasc Surg
106 : 912-917, 1993
53. Pompilio G, Polvani GL, Rossoni G, Porqueddu
M, Berti F, Barajon I, Petruccioli MG, Guarion
A, Aguggini G, Biglioli P, Sala A : Effects of
warm ishcemia on valve endothelium. AnnThorac
Surg 63 : 656-662, 1997
54. Yankah AC, Randzio G, Wottge HU, Bernhard
A : Factors influencing endothelial-cell viability
during procurement and preservation of valve
allografts. In : Thiede A, Doltz E, Engemann R,
Hamelmann H, eds. Microsurgical models in
rats for transplantation research. Springer-Verlag
Heidelberg, 1985, pp 107-111
55. Yankah AC, Dreyer W, Wottge HU, Muller-Rucholtz
W, Bernhard A : Kinetics of endothelial cells pre-
served aortic valve allografts used for heterotopic
transplantation in inbred rat strains. In : Bodnar
E, Yacoub MH, eds. Biologic and bioprosthetic
valves. Yorke Medical Books, New York, 1986,
pp 73-84
56. Yankah AC, Wottge HU, Muller-Ruchholtz W.
Short-course cyclosporin A therapy for definite
allograft valves survival immunosuppression in
allograft valve operations. Ann Thorac Surg 60 :
S146-150, 1995
57. Lester WM, Damji AA, Tanaka M, and Gedeon
I : Bovine mitral valve organ culture : role of
interstitial cells in repair of valvular injury. J
Mol Cell Cardiol 24 : 43-53, 1992
58. Mcgregor CGA, Bradley JF,Mcgee JO,Wheatley
DJ : Tissue culture, protein and collagen syn-
thesis in antibiotic sterilized canine heart valves.
Cardiovascular Research 10 : 389-393, 1976
59. Henney AM, Parker DJ, and Davies MJ : Col-
lagen biosynthesis in normal and abnormal hu-
man heart valves. Cardiovascular Research 16 :
624-630, 1982
60. SimionescuA, SimionescuD,Deac R : Biochemical
pathways of tissue degeneration in bioprosthetic
cardiac valves. ASAIO Journal 43 : M561, 1996
61. Woessner JF Jr : Matrix metalloproteinases and
their inhibitors in connective tissue remodeling.
FASEB J 5 : 2145-2154, 1991
62. Gogly B, Groult N, Hornebeck W, Godeau G,
Pellat B : Collagen zymography as a sensitive
and specific technique for the determination of
subpicogram levels of interstitial collagenase.
１３１The Journal of Medical Investigation Vol. 48 2001
Anal Biochem 255 : 211-216, 1998
63. Cagliero E, Roth T, Roy S, Maiello M, Lorenzi
M : Expression of genes related to the extracellular
matrix in human endothelial cells : differential
modulation by elevated glucose concentrations,
phorbol esters, and cAMP. J Biol Chem 266 :
14244 -14250, 1991
64. Belkhiri A, Richards C, Whaley M, McQueen
SA, Orr FW : Increased expression of activated
matrix metalloproteinase-2 by human endothelial
cells after sublethal H2O2 exposure. Lab Invest
77 : 533-539, 1997
65. Bendeck MP, Zempo N, Clowes AW, Galardy
RE, Reidy MA : Smooth muscle cell migration
and matrix metalloproteinase expression after
arterial injury in the rat. Circ Res. 75 : 539-545,
1994
66. Tyagi SC, Kumar S, Katwa L : Differential regu-
lation of extracellular matrix metalloproteinase
and tissue inhibitor by heparin and choleste-
rol in fibroblast cells. J Mol Cell Cardiol 29 :
391-404, 1997
67. Danielsen CC, Wiggers H, Andersen HR : In-
creased amounts of collagenase and gelatinase
in porcine myocardium following ischemia and
reperfusion. J Moll Cell Cardiol 30 : 1431-1442,
1998
68. Cleutjens JP, Kandala JC, Guarda E, Guntaka
RV, Weber KT : Regulation of collagen degra-
dation in the rat myocardium after infarction.
J Mol Cell Cardiol. 27 : 1281-1292, 1995
69. Guarda E, Myers PR, Brilla CG, Tyagi SC,Weber
KT : Endothelial cell induced modulation of car-
diac fibroblast collagen metabolism. Cardiovasc
Res 27 : 1004-1008, 1993
70. Villanueva AG, Farber HW, Rounds S, Goldstein
RH : Stimulation of fibroblast collagen and total
protein formation by an endothelial cell-derived
factor. Circ Res 69 : 134 -141, 1991
71. Curci JA, Petrinec D, Liao S, Golub LM, Thompson
RW : Pharmacologic suppression of experimen-
tal abdominal aortic aneurysms : a comparison
of doxycycline and four chemically modified
tetracycline. J Vasc Surg 28 : 1082-1093, 1998
72. Boyle JR, McDermott E, Growther M, Wills AD,
Bell PRF, Thompson MM : Doxycycline inhibits
elastin degradation and reduces metalloproteinase
activity in a model of aneurysmal disease. J Vasc
Surg 27 : 354-361, 1998
73. Porter KE, Loftus IM, Peterson M, Bell PR,
London NJ, Thompson MM : Marimastat inhib-
its neoinitimal thickening in a model of human
vein graft stenosis. Br J of Surg 85 : 1373-1377,
1998
74. De Smet BJ, de Kleijn D, Hanemaaijer R, Verheijen
JH, Robertus L, van Der Helm YJ, Post MJ.
Metalloproteinase inhibition reduces constric-
tive arterial remodeling after balloon angioplasty :
a study in the atherosclerotic Yucatan micropig.
Circulation 101 : 2962-2967, 2000
75. Bigatel DA, Elmore JR, Carey DJ, Cizmeci-Smith G,
Franklin DP, Youkey JR : Thematrixmetalloproteinase
inhibitor BB-94 limits expansion of experimen-
tal abdominal aortic aneurysms. J Vasc Surg
29 : 130-139, 1999
T. Kitagawa et al. Cellular biology of cryopreserved allograft valves１３２
